Usona Institute will begin its Phase 3 Clinical Trial investigating psilocybin for Major Depressive Disorder (MDD), the company announced today.
According to a release, the uAspire trial will start with an initial six-week randomized double-blind treatment period. Participants will be monitored for one year to characterize the treatment durability and long-term safety of psilocybin treatment.
Hear from former winners of the #Wisconsin Governor's Business Plan Contest at our #Innovation Network Luncheon on 5/9 the @uwm's Innovation Accelerator in Wauwatosa!
Learn more and register: https://loom.ly/npKwq2Y #startup
Check out the latest #tech- and #entrepreneurial-related news, events and #jobopportunities in our newsletter! https://loom.ly/xG_9cJ0
.@gener8tor #Madison invests $600k in six startups. https://loom.ly/onW9GQQ #entrepreneur #startup
.@uwhealth: Clinical trial examines new way of eliminating kidney stones. https://loom.ly/kvnwoIU via @wisbusiness #clinicaltrials #clinicalresearch
Clinical trial examines new way of eliminating kidney stones. https://loom.ly/KWAtQT0 via @wisbusiness #clinicaltrials #clinialresearch
.@uwgb, @stnorbert #partnership lets #students study at both schools. via @wpr #education
UW-Green Bay, St. Norbert partnership lets students study at both schools
The University of Wisconsin-Green Bay and St. Norbert College are partnering to let students seamlessly study at both schools beginning this fall.
loom.ly
;
